Core Viewpoint - Genting New Year (01952) saw a significant increase in stock price, rising over 3% to HKD 46.2, with a trading volume of HKD 1.8711 million, following announcements of insider purchases by key executives and shareholders [1] Group 1: Insider Purchases - Non-executive director and major shareholder Mr. Fu Wei purchased 339,000 shares, while Executive Chairman Mr. Wu Yifang bought 277,000 shares, CEO Mr. Luo Yongqing acquired 132,500 shares, and CFO Ms. He Ying purchased 98,200 shares, with a total expenditure exceeding HKD 38 million [1] - The average purchase price for the shares was approximately HKD 45.01 each [1] Group 2: Shareholder Commitment - Major shareholder Kangqiao Capital has committed to increasing its shareholding by no more than 1% over the next three to six months, subject to market conditions and applicable laws and regulations [1]

Core Viewpoint - Genting New Year (01952) saw a significant increase in stock price, rising over 3% to HKD 46.2, with a trading volume of HKD 1.8711 million [1] Group 1: Insider Transactions - Non-executive director and major shareholder Mr. Fu Wei purchased 339,000 shares, while Executive Chairman Ms. Wu Yifang bought 277,000 shares, CEO Mr. Luo Yongqing acquired 132,500 shares, and CFO Ms. He Ying purchased 98,200 shares, with a total expenditure exceeding HKD 38 million [1] - The average purchase price for the shares was approximately HKD 45.01 each [1] Group 2: Shareholding Commitment - Major shareholder Kangqiao Capital has committed to increasing its shareholding by no more than 1% over the next three to six months, subject to market conditions and applicable laws and regulations [1]

公司获告知，在视市场状况及在适用法律及监管的规限下，康桥资本(作为公司主要股东)已进一步承诺 其计划于未来三至六个月内将其持股比例累计增加不多于1%。 董事会相信，董事透过场内收购股份进行的自愿购股，以及康桥资本作出的承诺，均彰显了对公司未来 前景及长远发展的坚定信心。 智通财经APP讯，云顶新耀(01952)发布公告，于2025年12月12日，傅唯先生(非执行董事、董事会荣誉 主席兼公司主要股东)、吴以芳先生(执行董事兼董事会主席)、罗永庆先生(执行董事兼公司首席执行官) 及何颖先生(执行董事、总裁兼公司首席财务官)分别于市场购入33.9万股、27.7万股、13.25万股及9.82 万股公司普通股，总代价超过3800万港元，平均价格约为每股股份45.01港元。 ...

董事会相信，董事透过场内收购股份进行的自愿购股，以及康桥资本作出的承诺，均彰显了对公司未来 前景及长远发展的坚定信心。 公司获告知，在视市场状况及在适用法律及监管的规限下，康桥资本(作为公司主要股东)已进一步承诺 其计划于未来三至六个月内将其持股比例累计增加不多于1%。 云顶新耀(01952)发布公告，于2025年12月12日，傅唯先生(非执行董事、董事会荣誉主席兼公司主要股 东)、吴以芳先生(执行董事兼董事会主席)、罗永庆先生(执行董事兼公司首席执行官)及何颖先生(执行董 事、总裁兼公司首席财务官)分别于市场购入33.9万股、27.7万股、13.25万股及9.82万股公司普通股，总 代价超过3800万港元，平均价格约为每股股份45.01港元。 ...

公告显示，公司非执行董事、董事会荣誉主席兼本公司主要股东傅唯先生，执行董事兼董事会主席吴以 芳先生，执行董事兼本公司首席执行官罗永庆先生，以及执行董事、总裁兼本公司首席财务官何颖先生 分别于市场购入339,000股、277,000股、132,500股及98,159股本公司普通股，总金额超过3,800万港元， 平均价格约为每股股份45.01港元。 云顶新耀将于2025年12月15日上午8时举行中文线上投资人会议，公司董事会及管理层将在会上同步更 新战略规划与经营情况，并展示公司在创新药研发、商业化和全球化布局上的清晰规划和前瞻性布局， 呈现持续创造价值的能力。 2025年12月12日，云顶新耀（1952.HK）对外发布董事及主要股东增持公司股份的相关公告，披露公司 多位董事及主要股东近期通过场内交易增持公司股份，并作出进一步增持承诺，不仅彰显对公司未来发 展前景的信心，更向市场传递出强烈的积极信号。 此外，作为公司主要股东的康桥资本亦在公告中明确表示，在视市场状况及在适用法律及监管的规限 下，进一步承诺计划于未来三至六个月内将其持股比例累计增加不多于1%。 ...

本公司董事（「董事」）會（「董事會」）宣佈，於2025年12月12日，傅唯先生（ 非執行 董 事 、 董 事 會 榮 譽 主 席 兼 本 公 司 主 要 股 東 ）、 吳 以 芳 先 生（ 執 行 董 事 兼 董 事 會 主 席 ）、羅永慶先生（ 執行董事兼本公司首席執行官 ）及何穎先生（ 執行董事、總裁兼 本公司首席財務官 ）分別於市場購入339,000股、277,000股、132,500股及98,159股 本 公 司 普 通 股（「 股 份 」）， 總 代 價 超 過 38,000,000 港 元 ， 平 均 價 格 約 為 每 股 股 份 45.01港元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲頂新耀有限公司 自願公告 本公司董事及主要股東增持股份 本公告由雲頂新耀有限公司（「本公司」）自願作出。 本公司股東及潛在投資者於買 ...

Market Performance - The Hong Kong stock market experienced a strong upward trend on December 12, with the Hang Seng Index rising by 446.28 points, or 1.75%, closing at 25,976.79 points [1] - The Hang Seng Tech Index increased by 103.46 points, or 1.87%, closing at 5,638.05 points [1] - The China Enterprises Index rose by 145.07 points, or 1.62%, closing at 9,079.35 points [1] - The Red Chip Index gained 47.77 points, or 1.16%, closing at 4,150.4 points [1] Sector Performance - Technology stocks saw significant gains, with NetEase rising over 4%, and Tencent, Alibaba, and Lenovo increasing by over 2% [1] - Power equipment stocks surged, with Dongfang Electric rising over 13% [1] - Gold stocks generally rose, with Zijin Mining International increasing by over 3% [1] - Chinese brokerage stocks saw a late rally, with China Galaxy rising over 6% [1] - Insurance stocks strengthened in the afternoon, with China Pacific Insurance and China Life both rising over 5% [1] - AIGC concept stocks and real estate blue-chip stocks also saw gains [1] - However, the Everbright system and tobacco stocks declined [1] Company News - Hong Kong Electronic Commerce reported a total merchandise transaction value of HKD 636 million in November, a year-on-year decrease of 7.4% [2] - BOE Technology Group signed a total product processing agreement with its Vietnam subsidiary [2] - China Galaxy completed the issuance of a short-term corporate bond worth 4 billion yuan [2] - Cloudy Technology plans to establish a joint venture focusing on innovative robotic solutions [3] - Cloudtop New Horizon signed a commercialization service agreement with Haisen Bio [3] - Peijia Medical's TaurusTrio transcatheter aortic valve system received approval from the National Medical Products Administration [3] - China Antibody's SM17 new drug research application was accepted by the National Medical Products Administration [4] - Hengyi Holdings plans to undergo capital restructuring and fundraising activities [5] Institutional Insights - GF Securities noted that the Hong Kong stock market is more sensitive to external risks, with potential rebounds expected in mid to late December and early January [6] - Dongwu Securities believes the market is still in a left-side phase, requiring patience for a rebound [6] - Everbright Securities indicated that while there is significant room for growth compared to previous bull markets, the current market may lack strong catalysts [6] - Guoxin Securities highlighted that the recent net inflow of southbound funds into the Hong Kong market exceeded 110 billion yuan in November, indicating strong liquidity and a willingness to invest at lower levels [6] - The forecast for the Hong Kong market in 2026 is expected to range between 30,000 and 32,000 points [6] Industry Trends - The ice and snow economy is emerging as a new growth point, encompassing ice and snow sports, tourism, equipment, and culture [7] - This sector is characterized by a long industrial chain, significant spillover effects, and high social benefits, contributing to regional economic development [7] - The increasing popularity of ice and snow sports and tourism is transforming "cold resources" into a "hot economy," leading to rapid growth in the ice and snow industry [7] - There is a recommendation to focus on ice and snow sports brands with marginal improvements and stable dividend-paying leading companies [7]

Core Insights - CloudTop New Horizon (1952.HK) announced strategic cooperation agreements with Haisen Biopharmaceuticals, including a commercialization service agreement and a licensing agreement [1][2] Group 1: Commercialization Service Agreement - CloudTop New Horizon's subsidiary will provide commercialization services for six mature products from Haisen Biopharmaceuticals, including Ceftriaxone, Somatostatin, Urapidil, Azilsartan, Candesartan, and Voglibose [1] - The service fee will range from 20% to 55% of the quarterly net sales of the relevant products, with annual payment caps of 560 million, 616 million, and 677 million yuan for the years 2026 to 2028 [1] Group 2: Licensing Agreement - The licensing agreement grants CloudTop New Horizon exclusive rights to conduct further clinical development, registration, and commercialization of Lerodalcibep in Greater China [2] - Lerodalcibep is a third-generation PCSK9 inhibitor aimed at lowering LDL-C levels in patients with high cholesterol, with a significant unmet medical need in China [2] - The product is expected to submit a biopharmaceutical application in Greater China in the first half of 2026, with potential approval and market launch by 2027 [2]

每经AI快讯，云顶新耀(01952.HK)午后涨超4%，截至发稿，涨4.65%，报45.8港元，成交额1.72亿港 元。 （文章来源：每日经济新闻） ...

Core Viewpoint - Genting New Year (01952) has seen a stock price increase of over 4%, currently trading at 45.8 HKD, with a transaction volume of 172 million HKD, following the announcement of two strategic cooperation agreements with Haisen Biopharmaceutical [1] Group 1: Strategic Agreements - Genting New Year’s wholly-owned subsidiary, Genting New Year Pharmaceutical Technology, has signed two strategic cooperation agreements with Haisen Biopharmaceutical [1] - Under the commercialization service agreement, Genting New Year Pharmaceutical Technology will leverage its existing sales and marketing system to provide commercialization services for six mature products from Haisen Biopharmaceutical, focusing on critical care, cardiovascular, and metabolic fields [1] Group 2: Licensing Agreement - The licensing agreement grants Genting New Year Pharmaceutical Technology exclusive rights to conduct further clinical development, registration, and commercialization of Lerodalcibep in Greater China, enhancing its late-stage pipeline [1] - According to the licensing agreement, Genting New Year Pharmaceutical Technology will make an initial payment of approximately 205 million CNY, with potential development and regulatory milestone payments not exceeding 212 million CNY, and potential sales milestone payments not exceeding 1.977 billion CNY, along with potential royalties based on net sales [1]